This inventor holds 3 USPTO granted patents and 3 published patent applications. Top assignees: Viela Bio, Inc., Medimmune Limited. Active years: 2018-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018-2023
Title: Julie Ann Douthwaite: Innovator in ILT7 Binding Molecules
Introduction: Julie Ann Douthwaite is a prominent inventor based in Cambridge, GB, known for her significant contributions to the field of biomedicine. With a notable track record of three patents, she has focused on developing innovative solutions for conditions associated with ILT7-expressing cells, particularly in the realm of autoimmune diseases.
Latest Patents: One of Julie's latest patents, titled "ILT7 binding molecules and methods of using the same," is directed towards ILT7 binding molecules, such as anti-ILT7 antibodies. This invention outlines methods for treating or preventing various conditions and diseases linked to ILT7-expressing cells, marking a substantial advancement in therapeutic options for autoimmune diseases. The innovative nature of her work underscores her dedication to improving health outcomes through targeted molecular therapies.
Career Highlights: Throughout her career, Julie has worked with leading companies in the biotechnology industry, including Viela Bio, Inc. and Medimmune Limited. Her experience in these organizations has enabled her to refine her expertise in the development and application of biopharmaceuticals, contributing to her reputation as an influential inventor in her field.
Collaborations: Collaboration has been a key aspect of Julie's professional journey. She has had the opportunity to work alongside esteemed colleagues such as Katherine Ann Vousden and Melissa Marie Damschroder. These partnerships have allowed her to share insights and foster innovation in the development of new therapeutic approaches.
Conclusion: Julie Ann Douthwaite exemplifies the spirit of innovation in biotechnology, particularly with her development of ILT7 binding molecules. Her contributions are paving the way for new treatments that have the potential to change lives for patients suffering from autoimmune diseases. With a strong foundation in both research and collaboration, Julie continues to play a pivotal role in advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile